Company / Cash & Equivalents
DaVita Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$676.4M
FY2025
5-year range
$244.1M / $794.9M
FY2021-FY2025
Trend
-14.9%
vs FY2024
Sector context
#38 of 148
Health Care
What the data says
At $676M, DaVita's cash & equivalents ranks #38 of 148 in the Health Care sector. Cash & Equivalents has fluctuated over the past 10 years, ranging from $244M in FY2022 to $1.1B in FY2019.
Based on SEC 10-K filings.
$676M in FY2025 with a 5-year CAGR of +15.8%.
Improved from $380M to $676M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +40.5%
- 5-Year CAGR
- +15.8%
- 10-Year CAGR
- -
Sector benchmark
#38 of 148 in Health CareTop 26% of 148This company $676.4M Sector average $1.2B
▼
-42.5% below sector average
Key checks
Key Insights
- 5-year CAGR of +15.8%, indicating consistent growth.
- In FY2025, cash & equivalents decreased 14.9% year-over-year.
- Ranks #38 out of 148 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2019.
Company context
Key Data Points
- Altman Z-Score 1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $676.4M | -14.9% |
| FY2024 | $794.9M | +109.2% |
| FY2023 | $380.1M | +55.7% |
| FY2022 | $244.1M | -47.2% |
| FY2021 | $461.9M | +42.1% |
| FY2020 | $325.0M | -70.5% |
| FY2019 | $1.1B | +241.3% |
| FY2018 | $323.0M | -36.4% |
| FY2017 | $508.2M | -24.7% |
| FY2016 | $674.8M | -45.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026